240 related articles for article (PubMed ID: 35058083)
1. Successful treatment with dimethyl fumarate in a child with relapsing-remitting multiple sclerosis.
Saijo N; Abe Y; Oikawa Y; Okubo Y; Endo W; Numata-Uematsu Y; Takahashi T; Uematsu M
Brain Dev; 2022 May; 44(5):353-356. PubMed ID: 35058083
[TBL] [Abstract][Full Text] [Related]
2. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate.
Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M
Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
[TBL] [Abstract][Full Text] [Related]
4. Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.
Havrdova E; Giovannoni G; Gold R; Fox RJ; Kappos L; Phillips JT; Okwuokenye M; Marantz JL
Eur J Neurol; 2017 May; 24(5):726-733. PubMed ID: 28328179
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908
[TBL] [Abstract][Full Text] [Related]
6. Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study.
Naismith RT; Wundes A; Ziemssen T; Jasinska E; Freedman MS; Lembo AJ; Selmaj K; Bidollari I; Chen H; Hanna J; Leigh-Pemberton R; Lopez-Bresnahan M; Lyons J; Miller C; Rezendes D; Wolinsky JS;
CNS Drugs; 2020 Feb; 34(2):185-196. PubMed ID: 31953790
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T
J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273
[TBL] [Abstract][Full Text] [Related]
8. Simple parameters from complete blood count predict lymphopenia, adverse effects and efficacy in people with MS treated with dimethyl fumarate.
Baeva ME; Metz LM; Greenfield J; Camara-Lemarroy CR
Mult Scler Relat Disord; 2023 Jun; 74():104699. PubMed ID: 37031552
[TBL] [Abstract][Full Text] [Related]
9. Whole blood miRNAs in relapsing MS patients treated with dimethyl fumarate in the phase 4 TREMEND trial.
Elkjaer ML; Lohse RM; Burton M; Mendoza JP; Thomassen M; Sejbaek T; Illes Z
J Neuroimmunol; 2023 Aug; 381():578145. PubMed ID: 37393851
[TBL] [Abstract][Full Text] [Related]
10. Dimethyl Fumarate: A Review in Relapsing-Remitting MS.
Deeks ED
Drugs; 2016 Feb; 76(2):243-54. PubMed ID: 26689201
[TBL] [Abstract][Full Text] [Related]
11. Fulminant rebound of relapsing-remitting multiple sclerosis after discontinuation of dimethyl fumarate: A case report.
Harmel P; Schlunk F; Harms L
Mult Scler; 2018 Jul; 24(8):1131-1133. PubMed ID: 29708444
[TBL] [Abstract][Full Text] [Related]
12. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
[TBL] [Abstract][Full Text] [Related]
13. Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center.
Smoot K; Spinelli KJ; Stuchiner T; Lucas L; Chen C; Grote L; Baraban E; Kresa-Reahl K; Cohan S
Mult Scler; 2018 Jun; 24(7):942-950. PubMed ID: 28537110
[TBL] [Abstract][Full Text] [Related]
14. Dimethyl fumarate: a possible exit strategy from natalizumab treatment in patients with multiple sclerosis at risk for severe adverse events.
Calabrese M; Pitteri M; Farina G; Bajrami A; Castellaro M; Magliozzi R; Monaco S
J Neurol Neurosurg Psychiatry; 2017 Dec; 88(12):1073-1078. PubMed ID: 28844068
[TBL] [Abstract][Full Text] [Related]
15. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
16. Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis.
Müller J; Schädelin S; Lorscheider J; Benkert P; Hänni P; Schmid J; Kuhle J; Derfuss T; Granziera C; Yaldizli Ö
Eur J Neurol; 2023 Dec; 30(12):3809-3818. PubMed ID: 37578431
[TBL] [Abstract][Full Text] [Related]
17. Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews.
Gudesblatt M; Roman C; Singer BA; Schmidt H; Thomas J; Shankar SL; Lyons J; Kapadia S
Adv Ther; 2022 Jul; 39(7):3199-3213. PubMed ID: 35556227
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada.
Su W; Kansal A; Vicente C; Deniz B; Sarda S
J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475
[TBL] [Abstract][Full Text] [Related]
19. Relapses Requiring Intravenous Steroid Use and Multiple-Sclerosis-related Hospitalizations: Integrated Analysis of the Delayed-release Dimethyl Fumarate Phase III Studies.
Giovannoni G; Gold R; Fox RJ; Kappos L; Kita M; Yang M; Sarda SP; Zhang R; Viglietta V; Havrdova E
Clin Ther; 2015 Nov; 37(11):2543-51. PubMed ID: 26526385
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of dimethyl fumarate for the treatment of relapsing remitting multiple sclerosis.
Valencia-Sanchez C; Carter JL
Expert Opin Pharmacother; 2020 Aug; 21(12):1399-1405. PubMed ID: 32543241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
